The company mainly operates through two segments, i.e. healthcare services and pharmacy, which contribute 55 per cent and 40 per cent, respectively, towards its total revenue. Over the last five years, the healthcare segment grew by 13 per cent CAGR and the pharmacy segment by 24 per cent CAGR. It has added new hospitals in Tamil Nadu, Andhra Pradesh and Telangana, which would drive its revenue in the near term. Also, its number of pharmacy stores have touched 3085, of which 64 stores were added in Q1FY19. The rising revenue from the existing stores have added to the growth of this segment. The management has assured completion of capex and it is optimistic about improvement in margins. In Q1FY19, the company delivered robust growth in topline and profits on QoQ and YoY basis. Considering these factors, we recommend it as a BUY.